Business Context and Reporting Period
This Form 8-K Current Report was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on July 1, 2014, reporting events occurring on June 30, 2014. The company is a Delaware corporation headquartered in San Diego, California, with a wholly-owned subsidiary, Etherogen, Inc.
Key Financial Metrics and Debt
The filing discloses the entry into a material definitive agreement involving a new term loan. Specific revenue, profit, cash flow, or margin data is not provided in this document.
- Debt Instrument: $15 million Term Loan.
- Lenders: Oxford Finance LLC and Silicon Valley Bank.
- Interest Rate: 7.00% per annum.
- Repayment Terms: Interest-only payments monthly until August 1, 2015. Principal and interest payments commence thereafter.
- Maturity Date: July 1, 2018.
- Collateral: Secured by all company assets except intellectual property (which is subject to a negative pledge).
- Equity Component: Lenders received warrants to purchase 85,470 shares of common stock at an exercise price of $3.51 per share, exercisable for ten years.
Material Changes and Conditions
The primary material change is the creation of a direct financial obligation of $15 million. A conditional extension of the interest-only payment period exists: if the Company receives at least $30 million in net proceeds from an equity offering, the interest-only period extends to February 1, 2016. The filing does not provide comparative financial data against prior periods.
Outlook, Risks, and Unusual Items
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard obligations of the loan agreement. The issuance of the warrants was deemed exempt from registration under Section 4(a)(2) of the Securities Act of 1933, relying on the status of recipients as accredited investors.
Investor Verification Checklist
- Verify the company name discrepancy: The filing is for Trovagene, Inc., not Cardiff Oncology, Inc.
- Confirm the status of the $30 million equity offering required to extend the interest-only period.
- Review the attached Loan and Security Agreement (Exhibit 10.1) for specific covenants and default provisions.
- Assess the dilution impact of the 85,470 warrants issued to lenders.
- Check subsequent filings for the actual cash proceeds received and the utilization of the $15 million loan.